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ScienceDirectAdoptive transfer of T cells gene-engineered with antigen-
specific receptors, whether it be chimeric antigen receptors
(CARs) or T cell receptors (TCRs), has proven its feasibility and
therapeutic potential in the treatment of tumors. Despite clinical
successes, the majority of patients experiences no or non-
sustainable clearance of solid tumors, which is attributed to
local T cell evasive mechanisms. A rapidly expanding
understanding of molecular and cellular events that contribute
to a reduction in numbers and/or activation of intra-tumor T
cells has facilitated the development of gene-engineering
strategies, enabling T cells to counter immune tolerance. Here,
we present an overview of gene-engineering approaches and
considerations to improve tumor-selectivity and effectiveness
of adoptively transferred T cells.
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Engineering T cells to treat tumors: a short
introduction
The concept to combat malignant disease by utilizing the
patient’s own immune system has established itself as an
effective alternative and/or addition to treatments such as
surgery, chemotherapy or radiotherapy. A promising and
currently employed immune treatment is the adoptive
transfer of T cells (AT) engineered with chimeric antigen
receptors (CARs) or T cell receptors (TCRs). To this end,
patient-derived T cells are equipped with receptors rec-
ognizing a given tumor antigen, redirecting them to
selectively destroy cells expressing this antigen. While
the use of CARs has shown impressive results in B cell
leukemia’s (ALL) with objective and complete responses
(OR/CR) up to 94%, their current use in the treatment of
solid tumors is failing to corroborate the same successwww.sciencedirect.com (reviewed in [1]). TCR-engineered T cells have demon-
strated clinical benefit in patients with multiple myeloma
(OR: 80%; CR: 2%), metastatic melanoma (OR: 55%; CR:
6%) and metastatic synovial sarcoma (OR: 61%; CR: 20%)
(reviewed in [2]). These clinical results notwithstanding,
AT can be accompanied by therapy-related toxicities,
generally related to recognition of target antigens or
highly similar target antigens outside tumor tissue and
overt T cell activation [1,2]. In addition, in particular
when treating solid tumors, AT is generally marked by a
large fraction of patients with no clinical response and, in
case patients do respond, non-sustainability of responses.
This suboptimal success rate coincides with limited
accumulation and activation of T cells within tumors
and poor persistence of these cells in the periphery
[3,4]. In order to further enhance therapeutic efficacy,
gene engineered T cells need to address two major
challenges. First, receptors need to be selected that
mediate effective and safe T cell responses; and second,
local immune suppressive mechanisms need to be antag-
onized to ensure sufficient numbers and function of
therapeutic T cells at the tumor site.
In this perspective, we will shortly touch upon selection
of safe receptors to enable T cells to see tumor-specific
antigens. Subsequently, we will zoom in on specific
mechanisms employed by solid tumors to restrict accu-
mulation and activation of intra-tumoral T cells, and
outline gene-engineering approaches to overcome such
T cell evasive mechanisms.
T cell engineering: safe antigen-specific
receptors
When addressing therapeutic safety by choosing a suffi-
ciently immunogenic target antigen, it is critical to verify
that its expression is restricted to tumor cells, thus avoid-
ing possible destruction of healthy tissues. Once an anti-
gen is selected, antigen-binding moieties (as a source for
CARs) or TCRs can be obtained through various immu-
nization or molecular platforms. In case of TCRs, recep-
tors need to undergo stringent efficacy and specificity
assessment due to their intrinsic capacity of recognizing
multiple, highly similar epitopes sharing an identical
recognition motif. More detailed information on the
selection and evaluation of tumor antigens and corre-
sponding TCRs can be found in [5]. Another strategy
to address safety of AT entails incorporation of suicide
genes into therapeutic T cells. This approach, although
potentially valid in certain settings (reviewed in [6,7])
requires caution as it may not be compatible to the fastCurrent Opinion in Immunology 2018, 51:133–139
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trials (reviewed in [2]).
High numbers of active, intra-tumoral T cells
make all the difference
When shifting to therapeutic efficacy, there are several
lines of evidence pointing to the importance of high
numbers and activity of intra-tumoral CD8 T cells. First,
tissues that harbor highly effective CD8 T cells, such as
allo-rejected kidney transplants, show a distinctive signa-
ture of genes related to T cell trafficking and T cell
effector functions [8]. Second, it has been well-recog-
nized that a low number of immune effector cells, in
particular CD8 T cells, inside tumors are associated with
worse prognosis for various tumor types [9,10]. Moreover,
absence of local T cell immunity, when captured from the
expression of multiple genes that cover trafficking and
activity of effector T cells, predicts no or low responsive-
ness to immune therapies in a pan-cancer setting
[11,12]. Third, the predictive value of local T cell
immunity may go beyond the value of markers of mere
tumor antigenicity or mutational load [13–15].
How do tumors prevent accumulation and
activation of CD8 T cells?
The tumor micro-environment poses barriers towards
trafficking and intra-tumoral activation of T cells. The
trafficking of T cells towards tissue normally starts with
extravasation, which is often hampered by limited expres-
sion of T cell-specific adhesion molecules, co-stimulatory
ligands or chemoattractants by endothelial cells in the
setting of tumor tissue. Shut-down of T cell-specific
chemoattractants may be linked to epigenetic silencing
[16] or disruptive post-translational modifications [17,18].
Notably, tumor cell-derived molecules such as VEGF can
induce expression of FAS-ligand (FASL), which can
mediate killing of FAS-positive CD8 effector T cells
[19]. Following extravasation, T cells normally migrate
through supportive tissue, a process that is again hindered
in the setting of tumor tissue, with prominent roles for
cancer-associated fibroblasts and extracellular matrix
(ECM) components, such as type I collagen [20,21].
Even in case of successful trafficking towards and within
the tumor site, T cells will generally be confronted with
areas of hypoxia. Although hypoxia provides a stimulus
for neo-vascularization and breaking CD8 T cell toler-
ance to restore tissue homeostasis, sustained hypoxia is
accompanied by immature vasculature, CD8 T cell eva-
sion and tumor progression [22]. Amongst other mecha-
nisms, hypoxia is reported to decrease CD8 T cell num-
bers via enhanced production of TGFb1 by tumor cells as
well as enhanced numbers of T regulatory cells (Tregs)
and myeloid derived suppressor cells (MDSCs) [22–24].
In addition, tumor cells may reduce expression of co-
stimulatory ligands, such as B7-1, B7-2 or B7-H2, enhance
expression of co-inhibitory ligands, such as PD-L1 andCurrent Opinion in Immunology 2018, 51:133–139 PD-L2 [25], shield themselves with immune-suppressive
chemoattractants, such as CXCL12 [26], or demonstrate
enhanced necrotic cell death. A tumor micro-environ-
ment that is nutrient-poor and does not favor T cell
co-stimulation may push intra-tumoral T cells into meta-
bolic exhaustion [27]. Collectively, deficiency in num-
bers and/or activation of immune effector cells, in partic-
ular Th1 cells, provides insufficient intra-tumoral
inflammation and enables tumors to escape from CD8
T cells. Figure 1a depicts a selection of mechanisms that
tumors employ to become immune tolerant.
Gene-engineering to enhance accumulation
and activation of intra-tumoral CD8 T cells
To reinvigorate T cell responses, advanced gene-engi-
neering strategies have been developed. These strategies
are diverse in nature and depend on technical advance-
ments (nicely reviewed in [6,7]). Here, we zoom into
several gene-engineering strategies that enhance the
trafficking and/or intra-tumoral activation of T cells,
and which are illustrated in Figure 1b.
Gene-engineering addressing T cell trafficking
In order to enhance numbers of T cells, gene-engineering
strategies have been used to improve T cell extravasation
and migration towards and within tumors. One strategy
relies on gene-transducing T cells with chemokine recep-
tors, such as CXCR2, CCR2b and CX3CR1, where T cell
recruitment and responsiveness towards various tumors in
preclinical models improved [28–30]. Another strategy
that enhances T cell extravasation and inhibition of tumor
growth encompasses the targeting of the vasculature of
established tumors via T cells gene-engineered with a
CAR directed against VEGFR2 [31]. T cell migration
through supportive tissue was shown to benefit from
enforced expression of heparanase by T cells, facilitating
the degradation of extracellular matrix (ECM) compo-
nents, thereby contributing to tumor T cell infiltration
and anti-tumor activity [32].
Gene-engineering addressing T cell activation
In order to enhance intra-tumoral activation of adminis-
tered T cells, various approaches have been reported,
including (but not limited to): enhancement of T cell co-
stimulation; metabolic reprogramming of T cells; driving
T cells into an inflammatory phenotype; and resistance of
T cells towards tumor cell death. Addressing T cell co-
stimulation, one straightforward approach would entail
TALEN-mediated PD-1 gene inactivation, effectively
blocking this negative feedback loop in therapeutic T
cells [33]. Along the same line, depletion of the negative
regulators of T cell activation CBLB or adenosine 2A
receptors using small interfering RNAs, resulted in
enhanced anti-tumor efficacy of T cells [34,35]. To affect
only those T cells that recognize antigen within tumors,
CARs and TCRs have been developed that incorporate
co-signaling molecules to provide T cell activationwww.sciencedirect.com
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Figure 1
Current Opinion in Immunology
Gene-engineering of T cells to treat immune tolerant tumors. (a) Mechanisms of T cell evasion employed by tumor tissues; (b) Gene-engineering
approaches to make T cells cope with evasive mechanisms. (CAF = cancer associated fibroblast; ECM = extracellular matrix; MDSC = myeloid
derived suppressor cells; MHC = major histocompatibility complex.)without the need for co-stimulatory ligands. CARs
equipped with signaling modules derived from CD28
or CD137 have already demonstrated clinical benefit in
hematological malignancies [1], whereas CARs equipped
with modules derived from CD278 demonstrated devel-
opment of IFNg+/IL17+ T cells with enhanced anti-
tumor reactivity [36]. An alternative strategy involves
co-transduction of T cells with a CD28-containing
CAR and a CD137 ligand, resulting in enhanced thera-
peutic efficacy towards CD19-positive tumors [37]. With
respect to TCRs, Govers and colleagues showed that
incorporation of CD28 enhanced T cell responses
directed against melanoma [38]. Notably, when using
TCRs that incorporate CD278 these anti-tumor responses
became more pronounced and were accompanied by
increased intra-tumoral accumulation and prolonged
peripheral persistence of CD8 T cells (Kunert, manuscript
in preparation). Intriguingly, T cells equipped with such
co-stimulatory antigen-specific receptors are less prone to
intra-tumoral metabolic exhaustion, showing enhancedwww.sciencedirect.com mitochondrial biogenesis and oxidative phosphorylation
[39]. Notably, shifting metabolic pathways in T cells by
enforced expression of PGC1a or OPA1, involved in
mitochondrial biogenesis and fusion, respectively,
resulted in enhanced anti-tumor responses and T cell
persistence [27,40]. Besides metabolic constraints,
intra-tumoral T cells also face suppression through
release of potassium ions by dying, necrotic tumor cells,
often present in developing tumors. Genetic introduction
of the potassium channel Kv1.3 in T cells, and their
adoptive transfer into melanoma-bearing mice, resulted
in improved rejection of tumors [41].
T cell responsiveness towards immune-suppressive cyto-
kines, such as TGFb1, may be targeted through the
introduction of DNRII into T cells, a dominant-negative
receptor for this cytokine [42]. Another example includes
transduction of therapeutic T cells with a modified IL-4
receptor, equipped with an IL-7 signaling domain, thus
conveying tumor-generated and immune-suppressive IL-Current Opinion in Immunology 2018, 51:133–139
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of immune modulatory agents, such as inflammatory
cytokines, is often limited due to overt impact on immu-
nity, approaches that enable release at the tumor site are
of particular interest. To this end, CAR or TCR T cells
have been developed that harbor constructs from which
IL12 or IL18 are expressed under the control of nuclear
factor of activated T cells (NFAT). These were shown to
mediate improved anti-tumor effects upon administration
to mice [44,45]. T cells with inducible IL12 were
observed to yield toxicities both in mice and patients
with melanoma [45,46]. In contrast, T cells with induc-
ible IL18 showed clear anti-tumor effects which were
accompanied by enriched numbers of intra-tumoral CD8
T cells when treating melanoma-bearing mice [45], a
polarization towards Th1 cells and presence of inflamma-
tory immune cells when treating pancreatic cancer or lung
cancer-bearing mice [47] without detectable side effects.
Interestingly, in the latter study, IL18, combined with a
co-stimulatory CD28-containing CAR, resulted in potent
T cell skewing towards T-bethi, FoxO1lo cells, possibly
enabling T cells to resist metabolic exhaustion effector
differentiation. For an overview of gene-engineering
strategies to boost T cell trafficking and intra-tumoral
activation, please refer to Table 1.
Non-gene engineering strategies
Although this perspective focuses primarily on
approaches to counter CD8 T cell evasion by gene-
engineering, it needs mentioning that a myriad of non-
engineering approaches is currently also under investiga-
tion. Examples include: antibodies against checkpoints;
depletion of MDSC [48], or inhibitors of IDO1 to prevent
tryptophan shortage [49], CXCR4 to prevent cancer cell
shielding [26] or PTPN2 to override blockade of IFN
response pathways [50]. Interestingly, exposing gene-
engineered T cells prior to AT to inhibitors of FAS or
AKT signaling pathways has been shown to preserve the
pool of naı¨ve and early memory T cells and enhance in
vivo persistence and anti-tumor response [51].Table 1
Gene-engineering strategies to overcome selected shortcomings of T
Category of T cell evasion Gene-engineering str
T cell trafficking Expression of chemoattr
Expression of endothelia
Secretion of ECM-degra




Expression of ionic trans
Expression of modified r
Inducible secretion of in
a Gene-engineering strategies to overcome a selected shortcoming may h
properties, such as co-stimulation, metabolism and inflammation, may sha
Current Opinion in Immunology 2018, 51:133–139 As our understanding of the mechanisms that govern
immune escape grow, new possible targets for gene-
engineering and none-gene-engineering approaches
emerge. For example, antigen presentation and/or IFN
response pathways are considered critical for effective T
cell responses as evidenced by mutations in b2-micro-
globulin and JAK1/2 that associate with resistance to
checkpoint blockade and potentially other immune ther-
apies [52,53]. Similarly, oncogenic signaling pathways,
such as b-catenin and type I IFN signaling, have been
recognized for their contributions to CD8 T cell evasion
[54,55].
Future perspective of gene-engineering: a
new avenue of combination treatment
As detailed above, engineering T cells with antigen-
specific CARs or TCRs enables T cells to target tumor
cells with high specificity and sufficiently high avidity
towards a given antigen. While this measure equips T
cells with the potential to ‘see’ tumor cells, selection of
additional gene-engineering approaches is considered an
effective next step to ensure sufficient numbers and
activation of intra-tumoral T cells. Technical advance-
ments, such as the synthetic Notch (synNotch) platform
that dynamically enables conditional expression of recep-
tors or molecules [56], are expected to further facilitate
the therapeutic implementation of gene-engineering of
antigen-specific T cells. With an increased understanding
of how tumor type, patient characteristics and choice of
therapy affect disease progression and immune evasion, it
is necessary to not only generate patient-tailored and
disease-tailored gene-engineered T cells. Rather, it is
also important to refine methods to detect immune sup-
pressive mechanisms, such as immune genomic tools to
interrogate Next Generation Sequencing (NGS) data and
multiplex analysis of cellular and molecular markers in
tissues and blood. Information on presence of tumor-
selective target antigens, in combination with dominant
immune escape mechanisms, is expected to guide opti-
mal combination therapies [10]. cell immunitya
ategies to counter T cell evasion Refs.
actant receptor [28–30]





 that enhance mitochondrial activity [27,40]
port channel [41]
eceptors for suppressive cytokine [42,43]
flammatory cytokine [45,47]
ave beneficial effects towards other shortcomings as well since T cell
re common cellular and molecular pathways (see text for details).
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